Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya by Carren A Watsierah et al.
Watsierah et al. Malaria Journal 2012, 11:436
http://www.malariajournal.com/content/11/1/436RESEARCH Open AccessProvider knowledge of treatment policy and
dosing regimen with artemether-lumefantrine and
quinine in malaria-endemic areas of western Kenya
Carren A Watsierah1, Rosebella O Onyango1, James H Ombaka2, Benard O Abong’o2 and Collins Ouma2*Abstract
Background: Due to widespread anti-malarial drug resistance in many countries, Kenya included, artemisinin-based
Combination Therapy (ACT) has been adopted as the most effective treatment option against malaria.
Artemether-lumefantrine (AL) is the first-line ACT for treatment of uncomplicated malaria in Kenya, while quinine is
preferred for complicated and severe malaria. Information on the providers’ knowledge and practices prior to or
during AL and quinine implementation is scanty. The current study evaluated providers’ knowledge and practices
of treatment policy and dosing regimens with AL and quinine in the public, private and not-for-profit drug outlets.
Methods: A cross-sectional survey using three-stage sampling of 288 (126 public, 96 private and 66 not-for-profits)
providers in drug outlets was conducted in western Kenya in two Plasmodium falciparum-endemic regions with
varying malarial risk. Information on provider in-service training, knowledge (qualification, treatment policy, dosing
regimen, recently banned anti-malarials) and on practices (request for written prescription, prescription of AL, selling
partial packs and advice given to patients after prescription), was collected.
Results: Only 15.6% of providers in private outlets had received any in-service training on AL use. All (100%) in
public and majority (98.4%) in not-for-profit outlets mentioned AL as first line-treatment drug. Quinine was
mentioned as second-line drug by 47.9% in private outlets. A total of 92.0% in public, 57.3% in private and 78.8% in
not-for-profit outlets stated correct AL dose for adults. A total of 85.7% of providers in public, 30.2% in private and
41.0% in not-for-profit outlets were aware that SP recommendations changed from treatment for mild malaria to
IPTp in high risk areas. In-service training influenced treatment regimen for uncomplicated malaria (P = 0.039 and
P = 0.039) and severe malaria (P < 0.0001 and P = 0.002) in children and adults, respectively. Most (82.3%) of private
outlets sell partial packs of AL while 72.4% do not request for written prescription for AL. In-service training
influenced request for written prescription (P = 0.001), AL prescription (P < 0.0001) and selling of partial packs
(P < 0.0001).
Conclusion: Public-sector providers have higher knowledge on treatment policy and dosing regimen on
recommended anti-malarials. Changes in treatment guidelines should be accompanied by subsequent
implementation activities involving all sector players in unbiased strategies.* Correspondence: collinouma@yahoo.com
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The burden of malaria persists in many parts of Africa des-
pite the availability of many interventions that are focused
on preventive and therapeutic strategies [1]. Artemisinin-
based Combination Therapy (ACT) has been adopted as
the most effective treatment option against malaria in
many countries following the widespread malaria parasite
resistance to more affordable anti-malarial drugs such as
chloroquine and sulphadoxine-pyrimethamine (SP) [2].
Furthermore, quinine remains the most widely used anti-
malarial drug in the treatment of severe and complicated
malaria in many malaria-endemic regions [3,4]. Kenya
adopted the new malaria policy in 2004, which recom-
mended the use of artemether 20 mg-lumefantrine 120 mg
(AL) as the first-line drug for treatment of uncomplicated
malaria [4]. Apart from AL, other artemisinin-based com-
binations and monotherapy drugs are widely available and
easily accessed in private outlets in Kenya [5,6] and other
malaria-endemic countries [7].
The implementation of a policy is a continuous
process and involves many activities including, but not
limited to, in-service training (to update the personnel
in the field with new knowledge) and adoption of new
practices (which comes along with changes in treatment
policy). In Kenya, there is a greater effort in training of
health service providers in the public sector on the use
of ACT relative to the private sector despite the vital
role they play in malaria treatment [7,8]. Data on evalua-
tions of knowledge and practices before or during imple-
mentation of the ACT, and quinine as a second-line
anti-malarial in the private sector in relation to the other
sectors in malaria-endemic region of Kenya, is scanty
[8-11]. In addition, the multiple-dose regimens for most
ACT and quinine are rather more complicated in com-
parison to a single dose needed for SP. This situation
has further been complicated by the fact that previous
findings in Kenya demonstrate that only 11% of health
workers dispensing AL in public facilities were without
formal clinical qualification [8].
Studies on health-worker practices have reported
mixed findings. For example, a previous study to deter-
mine the predictors of quality of health-worker practices
reported failure of health workers to prescribe AL to all
deserving cases due to insufficient supply of AL [11].
This observation further raised fears of stockouts and
patients’ preferences for SP over AL because of its sim-
ple dosage [11]. In the same study, AL was provided free
to consumers, however, the health workers had to assess
and prioritize cases that they deemed deserved to receive
AL as it was considered expensive by the government.
Other practices included prescription of available drugs
such as amodiaquine since they were continuously sup-
plied to the health facilities despite the policy change to
ACT [11].The successful policy outcome in the appropriate use of
ACT and quinine, therefore, is dependent on provision of
suitable knowledge to the health providers in all drug
outlets and to consumers. Currently, literature on provi-
ders’ knowledge and practices on treatment policy and
dosing regimens on the use of AL following the policy
change in Kenya is dwindling. Despite the use of quinine
for decades, no study has been carried out to evaluate
providers’ knowledge on its use for malaria treatment in
Kenya. The current study evaluated providers’ knowledge
and practices of treatment policy and dosing regimens
with AL and quinine in the public, private and not-for-
profit drug outlets.
Methods
Study design and study area
A cross-sectional survey was conducted between February
and May 2012 in two regions of Nyanza Province that are
considered endemic for Plasmodium falciparum transmis-
sion, but with different levels of risk for malaria. The
regions are in the lowlands around Lake Victoria (Kisumu,
Siaya and Bondo regions), which are experiencing a holo-
endemic and stable P. falciparum transmission (altitude
0–1,300 m) and in the highlands of Kisii (Kisii, Gucha and
Nyamira regions), which are experiencing an epidemic
transmission (>1,300-1,750 m) [12].
Sample size and sampling
A three-stage sampling approach was used to survey
drug outlets. For each region, a list of public medical
facilities was compiled using a database obtained from
the Ministry of Health [13]. First, from each of the two
selected survey areas, the main public hospital was
selected, and then a further five hospitals under the
main facility were randomly sampled. Lastly, eight other
public outlets under each of the hospitals were surveyed,
bringing a total of 96. A matching number of private
outlets was randomly selected. All (66) not-for-profit
outlets and an additional 30 public health facilities were
sampled to reach the required sample size of 288. The
sample size of 288 was determined according to previous
WHO recommendations for this kind of studies [14]. An
outlet in the context of the current study was a regis-
tered/licensed dispensing site or any point of sale or
provision of anti-malarial drugs.
Data collection
Data were collected through interview by enumerators
who visited the outlets in pairs. Prior to data collection,
enumerators who had nursing qualification were trained
on the use of the tools, followed by pilot testing with
regular supervision in nine of each of the outlet type
(in the same study area but whose data were not
included in the study samples). Drug providers were
Table 1 Drug providers’ qualifications by the outlet type
Health qualification Public Private Not-for-profit
n = 126 n = 96 n = 66
Pharmacist 23 (18.3%) 52 (54.2%) 20 (30.3%)
Midwife 13 (10.3%) - 3 (4.5%)
Clinical officers 4 (3.2%) - -
Nurse 76 (60.3%) 1 (1.0%) 28 (42.4%)
Laboratory Technician - 3 (3.1%) 6 (9.0%)
Counsellors 6 (4.7%) 17 (13.5%) -
Shop Assistant - 4 (4.2%) -
Relative - 2 (2.7%) -
Others 4 (3.2%) 17 (13.5%) 9 (13.6%)
Analyses performed by Chi-square tests. *Statistically significant at P ≤ 0.05.




Public Private Not-for-profit P-value
n = 126 n = 96 n = 66
Yes 91 (72.2%) 15 (15.6%) 36 (54.5%) <0.0001*
No 20 (15.9%) 74 (77.0%) 27 (40.9%)
Do not know 16 (12.7%) 7 (7.3%) 3 (4.5%)
Analyses performed by Chi-square tests. *Statistically significant at P ≤ 0.05.
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sented to participate were asked two screening questions
to determine whether (1) the outlet had stocked AL
and/or quinine within the previous three months, and
(2) AL and/or quinine were available on the day of the
survey. All providers answering “yes” to at least one of
the questions were recruited and gave information about
the AL and/or quinine after informed consent was
obtained from them. In outlets with more than one
attendant, the person serving the clients at the time of
the survey provided the information. The information
collected included the type of qualification, any in-service
training in the past two years, knowledge of treatment
policy, knowledge of dosing regimen with AL and qui-
nine, and awareness of recently banned anti-malarials.
Practices of providers when dispensing AL and quinine
were evaluated. Practices evaluated included whether they
request for written prescription, prescribe AL, sell partial
packs and the advice they gave to clients when dispensing
AL. Ethical clearance to conduct the study was provided
by the Maseno University Ethical Review Committee.
Data management and statistical analysis
Data collected were checked in the field and at the end
of each day cleaned to ensure completeness, consistency,
credibility and eligibility. Information captured in open-
ended questionnaire to test provider knowledge of treat-
ment policy and dosing regimen and the practices
involved when dispensing AL and quinine from the
three outlet types, was coded and entered into Statistical
Package for Social Sciences (SPSS) (Version 19). For
comparison, chi-square analyses were used to test dif-
ferences in proportions, and logistic regression analysis
was used to determine whether training in the ACT
policy influenced knowledge and practices of the provi-
ders at the outlets. Statistical significance of all the ana-
lyses was assessed at a P ≤ 0.05.
Results
Providers’ type of health qualification
In the current study, a total of 288 drug providers were
interviewed. Included were level 5 hospitals, district/
sub-district hospitals, health centres and dispensaries. For
each of these, a matching private and not-for-profit outlet
was surveyed. When stratified into outlets, respondents
dispensing anti-malarials on the day of the survey in pub-
lic outlets were 126 (44.0%), private were 96 (33.0%) and
not-for-profit outlets were 66 (23.0%). The qualification of
the drug providers varied with the outlet type as shown in
Table 1. Overall, the majority were nurses 105 (36.5%),
with the other major group comprised of pharmacists 95
(33.0%). Counsellors were 23 (8.0%), midwives 16 (6.0%),
laboratory technicians 9 (2.0%), and clinical officers, rela-
tives and shop assistants each comprised of <5 (2.0%).Other training not mentioned in the questionnaire com-
prised of 30 (10.4%) and included community health
workers, nurse aids and nutritionists, who were mainly
dispensing in private and not-for-profit outlets. Additional
results revealed that there were more nurses dispensing
drugs in the public outlets (60.3%) than in the private (1%)
and not-for-profit (42.4%) outlets, while pharmacists were
commonly found in private (54.2%) relative to public
(18.3%) and not-for-profit (30.3%) outlets (Table 1).
In-service training of providers
Table 2 presents the proportion of staff receiving
in-service training by outlet type. Results revealed
that less than half of the respondents 142 (49.3%) had
received in-service training on the use of AL as a first
line-treatment of malaria within the two years prior to
the current study. The training was mainly performed by
non-governmental organizations (NGOs) 102 (72%)
(mainly Global Fund), although government personnel
offered health briefs regularly in the public facilities. The
proportion of those who have received training within the
previous two years were significantly higher in the pub-
lic 91 (72.2%) relative to the private outlets 15 (15.6%;
P < 0.0001; Table 2).
Provider knowledge of treatment policy with
artemether-lumefantrine and quinine
In order to establish the provider’s knowledge on treat-
ment policy with AL and quinine, the distribution of
proportions of providers’ knowledge against drug outlets
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providers with knowledge of treatment policy were at its
maximum in public outlets 126 (100.0%) and almost all 65
(98.4%) in not-for-profit relative to private 49 (51.0%).
These individuals were able to mention AL as first line-
treatment as recommended by the government for un-
complicated malaria. Similarly, those who were able to
name quinine correctly as treatment for severe malaria
and as a second-line anti-malarial were 121 (96.0%) in
public, 55 (83.3%) in not-for-profit and 46 (47.9%) in pri-
vate outlets. The proportions of those who knew that AL
is a first-line anti-malarial were significantly higher in the
public 126 (100.0%) and not-for-profit 65 (98.4%) relative
to private outlets 49 (51.0%; P < 0.0001) (Table 3).
Provider knowledge of dosing regimens with
artemether-lumefantrine and quinine
In order to establish providers’ knowledge on dosing
regimen with AL and quinine, the distributions of pro-
portions of providers’ knowledge on dosing regimen
against drug outlets was performed. Table 4 shows the
proportion of providers in public outlets that were able
to state the correct AL and quinine doses in comparison
with providers in private and not-for-profit settings. As
shown, the level of knowledge on AL (P < 0.0001) and
quinine (P < 0.0001) significantly differed across the out-
lets. Results further demonstrated significantly higher
proportions of providers’ correct knowledge at public
outlets 119 (94.4%) on AL doses in children weighing
9 kg (P < 0.0001) relative to private 75 (78.1%) and not-
for-profit 58 (78.8%). Of the participants in public out-
lets, a significantly (P < 0.0001) higher proportion 116
(92.0%), were able to state correctly the recommended
doses with AL for adults weighing 45 kg as compared
with 55 (57.3%) and 58 (78.8%) in private and not-for-
profit outlets, respectively (Table 4).
Provider awareness on currently banned drugs
When inquiries were made about recent government
bans on anti-malarials, more than half 164 (56.9%) of all
providers reported that they were aware of the most
recent government ban on some anti-malarials and cor-
rectly observed that SP recommendations changed from
treatment for mild malaria to Intermittent PreventiveTable 3 Provider knowledge of treatment policy by outlet typ
Treatment policy Public
n = 12
First-line treatment with AL Correctly 126 (1
Incorrectly 0 (0.00
Second-line treatment with quinine Correctly 121 (9
Incorrectly 5 (4.0%
Analyses performed by Chi-square tests. *Statistically significant at P ≤ 0.05.Treatment in Pregnancy (IpTp) in high risk areas. The
reason for this change was identified as malaria drug re-
sistance by 108 (37.5%) providers, although 83 (28.8%)
could not give any reason, while 97 (33.7%) gave other
reasons. Table 5 shows the provider awareness on recent
government ban by outlet type.
Associations between in-service training and knowledge
on treatment policy and drug regimen on
artemether-lumefantrine and quinine
Additional logistic regression analysis was performed to
identify knowledge variables that were associated with
in-service training of staff. Results revealed that correct
mentioning of drug recommended by government for
treatment of uncomplicated malaria (OR; 1.07, 95% CI,
1.03-2.44, P = 0.040), treatment regimen for uncomplicated
malaria in children (OR; 2.01, 95% CI, 1.66-3.83, P = 0.039)
and in adults (OR; 2.03, 95% CI, 1.68-3.80, P = 0.039), and
treatment regimen for severe malaria in children (OR; 2.66,
95% CI, 1.88-5.44, P < 0.0001) and in adults (OR; 2.01, 95%
CI, 1.88-4.25, P = 0.002) was positively influenced by
in-service training of the providers (Table 6).
Provider practices on ACT
Further inquiries on the provider practices when
dispensing ACT was carried out. Results showed that
providers who requested for written prescription when
dispensing AL was 109 (86.3%) in public, 22 (22.8%) in
private, and 52 (79.1%) in not-for-profit outlets. Provi-
ders who did prescribe AL to their customers were 86
(67.9%) in public, 13 (37.6%) in private and 19 (29.1%) in
not-for-profit outlets (Table 7). Further results demon-
strated that 79 (82.3%) providers in the private outlets
sell partial packs of AL, while only 50 (39.7%) of provi-
ders in public outlets advise taking first dose imme-
diately and stress on the need for adherence to timing
9 (7.1%). None of the providers mentioned the need to
take AL with a lot of fluids (Table 7).
Further logistic regression analyses demonstrated that re-
quest for written prescription (OR; 3.00, 95% CI, 2.45-10.4,
P = 0.001), prescription of AL (OR; 4.03, 95% CI, 2.99-14.7,
P < 0.0001) and selling of partial packs (OR; 3.79, 95% CI,
2.77-11.2, P < 0.0001) were positively influenced by the
in-service training of the provider (Table 8).e
Private Not-for-profit P-value
6 n = 96 n = 66
00.0%) 49 (51.0%) 65 (98.4%) <0.0001*
%) 47 (49.0%) 1 (1.6%)
6.0%) 46 (47.9%) 55 (83.3)% <0.0001*
) 50 (52.1) 11 (16.7%)
Table 4 Provider knowledge of dosing regimens of artemether-lumefantrine and quinine by outlet type
Public Private Not-for-profit P-value
n = 126 n = 96 n = 66
Children 9 kg Correct AL dose 119 (94.4%) 75 (78.1%) 58 (78.8%) <0.0001*
Incorrect AL dose 7 (5.6%) 21(21.9%) 8 (21.2%)
Correct quinine dose 111 (88.1%) 50 (52.1%) 37 (56.0%) <0.0001*
Incorrect quinine dose 15 (11.9%) 46 (47.9%) 29 (44.0%)
Adults 45 kg Correct AL dose 116 (92.0%) 55 (57.3%) 58 (78.8%) <0.0001*
Incorrect AL dose 10 (8.0%) 41 (42.7%) 8 (21.2%)
Correct quinine dose 112 (88.8%) 31 (32.3%) 43 (65.2%) <0.0001*
Incorrect quinine dose 14 (11.2%) 65 (67.7%) 23 (34.8%)
Analyses performed by Chi-square tests. *Statistically significant at P ≤ 0.05.
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This survey was performed six years after the government
of Kenya had adopted the policy on ACT for treatment of
malaria. This policy recommended the use of AL as a first-
line treatment for uncomplicated malaria, while quinine
was still preferred for treatment of complicated and severe
malaria. In 2010, the policy was universally changed to
include the use of ACT for only laboratory-confirmed ma-
laria cases [15,16]. The current study therefore compared
knowledge and practices in providers in public, private,
and not-for-profit outlets on treatment policy and dosing
regimen on recommended anti-malarials in malaria-prone
areas of western Kenya.
The results revealed that there were more in-service
trained personnel in the past two years dispensing drugs
in public outlets (72.2%). This figure surpassed the target
60% set up by the Ministry of Health (MoH) in 2006
[17] and was much higher than the figure (46%) previ-
ously reported in another study conducted one year after
the policy change in Kenya [8]. However, this proportion
trained is below a recent proposed target of 100% as per
the Division of Malaria Control (DOMC) Monitoring
and Evaluation report for 2013 [18]. The expansion of
the in-service training coverage in public facilities is
encouraging despite the fact that the private sector is
still lagging behind in training its drug providers. Further
findings demonstrated that a considerable bulk (45%) of
private outlet staff dispensing drugs had no clinical
qualification. This confirms previous findings in Kenya
and Democratic Republic of Congo [19,20] in which it





Correctly naming SP 108 (85.7%)
Naming other drugs 15 (11.9%)
Not aware about the ban 3 (2.4%)
Analyses performed by Chi-square tests. *Statistically significant at P ≤ 0.05.the private outlets were trained. The private-sector
qualification has been a staggering issue for a very long
time in developing countries despite the significant role
they play in medication management and provision of
relevant information to patients [21]. The findings in the
private sector were contrary to that in the not-for-profit
outlets in that a higher proportion of drug providers
(54.5%) were trained in the not-for-profit outlets. This
disparity in the proportion of those trained in private
vs not-for-profit outlets may be attributed to the fact
that the mission hospitals (which are the major outlets
in the not-for-profit category), receive government sup-
port and tend to effect policies enacted by the govern-
ment. The 54.5% training received in this sector is
nevertheless inadequate and may have been contributed
by the recent mushrooming of non-governmental in-
terventions in Nyanza Province (e.g. The Millenium
Villages Projects and Ogra Foundation), most of which
targets integrated management of HIV and AIDS and
malaria. The qualification of providers in this sub-sector
has not yet been evaluated. Meanwhile, for better results,
both the private and all players in the not-for-profit
sector need to be involved in the implementation of
ACT policy. In addition, the providers should have regu-
lar and adequate training in drug dispensation to ensure
correct administration of anti-malarials.
An interesting observation was that about half (49%)
of providers in private outlets could not mention AL as
first-line treatment for uncomplicated malaria, while
approximately 52% mentioned quinine incorrectly for
treatment of severe malaria. This observation providestlet type
Private Not-for-profit P-value
n = 96 n = 66
29 (30.2%) 27 (41.0%) <0.0001*
43 (44.8%) 27 (41.0%)
24 (25.0%) 12 (18.0%)
Table 6 Influence of in-service training on knowledge factors
OR 95% CI P-value
Drug recommended for treatment of uncomplicated malaria 1.07 1.03-2.44 0.040
Treatment regimen for uncomplicated malaria in a child weighing 9 kg 2.01 1.66-3.83 0.039
Treatment regimen for uncomplicated malaria in an adult weighing 45 kg 2.03 1.68-3.80 0.039
Drug for treatment of severe malaria 1.44 0.78-1.99 0.142
Treatment regimen for severe malaria in a child weighing 9 kg 2.66 1.88-5.44 <0.0001
Treatment regimen for severe malaria in an adult weighing 45 kg 2.01 1.88-4.25 0.002
Awareness of recent ban 1.51 0.65-2.01 0.158
Logistic regression analysis performed between dependent and independent variables to identify knowledge variables significantly associated with in-service
training of staff. The P-values in bold were statistically significant at P ≤ 0.05; OR = Odd Ratios. 95% CI = 95% Confidence Interval.
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on the treatment policy. The reason behind low know-
ledge of quinine could be attributed to it being less
frequently stocked by the private sector due to reasons,
such as: quinine is mostly prescribed as a second-line
drug and therefore most customers would only ask for it
after the failure of other drugs, or it is either less publi-
cized or not publicized at all in media, and there is
decreasing awareness about it, as compared to first-line
AL. Private providers tend to stock drugs that are fre-
quently sought by consumers as it was demonstrated in
a previous study that the type of drug acquired for use
in a particular region is influenced by awareness on the
type of anti-malarial in the market [22].
Questions were further raised on the dosing regimen
with AL and quinine for particular weights (children
weighing 9 kg and adults weighing 45 kg) for uniformity
and easy recording. Disparity was recorded in knowledgeTable 7 Provider practices on ACT by outlet type




Sells partial packs of AL Yes
No
Advice given when dispensing AL
Take first dose immediately
Need for adherence to timing
Verbal description of treatment course
Side effects
Drug interactions
Importance of adherence to treatment course
Taking with a lot of fluids
Others
None given
Distributions of proportions performed by Chi-square tests.of dosing regimen with the two anti-malarials in public,
private and not-for-profit outlets. For example, a gene-
rally higher knowledge of dosing regimen for both chil-
dren and adults was observed in public and not-for-
profit outlets. This was in part influenced by in-service
training by non-governmental bodies reported in this
study, an indication of need for training. Some studies
related to prescription of AL reported that incorrect
weight-specific prescriptions of AL were sporadic and
the packaging would have influenced dosing regimen
[23]. One previous study carried out in Tanzania concurs
with the current findings in that most dispensers in pri-
vate pharmacies could not state the dosing schedules of
AL without referring to the package leaflets [24]. A
higher knowledge of treatment regimen with quinine for
severe malaria in public outlets reported in the current
study could have potentially been influenced by the con-
current in-service training and health briefs, contrary toPublic Private Not-for-profit
(n = 126) (n = 96) (n = 66)
109 (86.3%) 22 (22.8%) 52 (79.1%)
17 (13.7%) 74 (77.2%) 14 (21.2%)
86 (67.9%) 13 (37.6%) 19 (29.1%)
40 (31.6%) 83 (72.4%) 47 (70.9%)
1 (1.0%) 79 (82.3%) 8 (12.1%)
125 (99.0%) 17 (17.7%) 58 (87.9%)
50 (39.7%) 8 (8.0%) 7 (11.2%)
9 (7.1%) 21 (21.8%) 53 (81.1%)
1(1.0%) 5 (5.2%) 1 (1.0%)
11 (8.7%) 10 (10.4%) -
- - 1 (1.0%)
45 (35.7%) 3 (3.0%) 3 (4.9%)
0 (0.0%) 0 (0.0%) 0 (0.0%)
2 (1.6%) 15 (15.6%) -
7 (5.6%) 35 (36.5%) 1 (1.9%)
Table 8 Influence of in-service training on provider
practices
PProvider’s practices OR 95% CI P-value
Request for written prescription 3.00 2.45-10.4 0.001
Prescription of AL 4.03 2.99-14.7 <0.0001
Selling partial packs of AL 3.79 2.77-11.2 <0.0001
Advice given when dispensing AL 1.5 0.77-2.06 0.208
Logistic regression analysis between independent and dependent variables
was used to identify practices that were associated with in-service training of
providers. The P-values in bold were statistically significant at P ≤ 0.05;
OR = Odd Ratios. 95% CI = 95% Confidence Interval.
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in which it was shown that training of the providers did
not improve the knowledge of the dosing schedule with
quinine among the Village Health Volunteers (VHV)
and pharmacy owners [25]. However, the reasons for the
differences on awareness level on the most recent ban
on anti-malarials being observed in the outlets still
remains unclear.
In the private and not-for-profit outlets, the providers
knew more than three symptoms of malaria, a good indica-
tion for subsequent prescription, even though the malaria
treatment guidelines still confine AL and quinine prescrip-
tion to registered pharmacies and should only be provided
to confirmed cases of malaria. It is important to mention
that although the guidelines insist on laboratory tests before
selling the policy-recommended drugs to customers, the
practice of providers in private outlets selling anti-malarials
without prescription has been observed in various outlets
in the study region and this practice was significantly influ-
enced by in-service training.
The providers at the drug outlets are charged with the
responsibility of advising their customers on all matters
pertaining to adherence to treatment schedule and proper
usage of drugs. These practices are to be enhanced by the
providers since the policy indicates that there should be
inclusion of a written prescription, sale of full doses of
drugs, and even advice to take the first dose immediately.
In addition, the providers should educate the patients on
the need for adherence, the possible side effects and the
need to take more fluids during the treatment. It is encou-
raged that the providers verbally describe the treatment
course and the importance of adherence.
The discrepancy in the practices by the providers in
private outlets is disquieting. The sale of partial packs of
AL shows lack of commitment to change even in the
face of ACT, despite the fact that the type and duration
of treatment in private outlets is determined by the cli-
ents’ ability to pay [26,27]. The low prescription of AL in
private and not-for-profit outlets could be attributed to
lack of or insufficient in-service training. This followed
the observation that training influenced the prescription
practice with better prescription seen in the public sector(67.9%). In a previous study exploring reasons for health
workers not prescribing AL despite the drug being in stock
at the public health facilities, it was observed that most of
the health workers were only responding to general health
system weaknesses leading to non-adherence to the treat-
ment guidelines [11]. A low level of prescriptions of the
nationally recommended drug was reported in yet another
study where only 26% of children who needed treatment
with AL received a prescription for this drug according to
national guidelines [23]. The deviation from the guidelines
observed in the current study shows inadequate skills and
knowledge in preparation for implementation of the new
policy in the private sector.
It is important to note that the difference in the outcome
observed in the current study is attributed to in-service
training and health briefs, which in essence should take
precedence in readiness for the on-going implementation
process. There is critical need to find an intervention
which would address this disparity, owing to the impor-
tance of this sector in health provision and given that
absence of training in AL policy influence drug-prescribing
practices in Kenya [28]. One way of increasing coverage
can be through training the trainers from the same sector
who will further train their counterparts. This has been
shown to improve malaria treatment in private drug out-
lets in Bungoma District in western Kenya prior to policy
change [29]. Another approach may be to train the drug
dispensers directly in organized workshops, give informa-
tion, sensitization and education on the new policy and
health briefs on quinine regimen, although this method
might be a more expensive endeavour for the government.
A previous study reported improvement on health-worker
performance in care and treatment of patients after con-
ducting educative seminars and training of health workers
[30], confirming a hypothesis of increased training and
awareness prior to implementation of a change in drug
policy.
Focus on public sector to implement policy change was
reported in a study previously carried out in Kenya a year
after the implementation process of the new malaria
policy [8]. In that study health workers were trained in a
cascade manner leading to an increased number of trained
providers [8]. The tendency to focus on public sector to
implement changes in new policy guidelines downplays
the call by the World Health Organization to include
private sector in malaria treatment due to their significant
role in pharmaceutical management and provision of
relevant information to patients, thus enhancing the im-
provement of rational drug use [21]. Formulation of good
policies may not be a guarantee for proper interpretation
of knowledge and practice. It must be accompanied by
sensitization for the achievement of the outcome. A recent
study carried out in neighbouring Tanzania reported posi-
tive results in achieving policy change through sensitization
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The current study had limitations in that it was only a
one-time point survey and thus it could not evaluate the
impact of other factors on provider’s knowledge and
practices on dispensation of antimalarial drugs. Further-
more, the current findings are based on a sample of 288
outlets. As such, it would be critical to carry out an
extensive longitudinal survey in a wider coverage of the
outlets in the endemic areas to exhaustively delineate
the impact of other factors on provider’s knowledge and
practices on dispensation of anti-malarial drugs.
Conclusion
Public-sector providers have better knowledge and better
practices on treatment policy and dosing regimen with
policy-recommended anti-malarials than their counter-
parts in private and not-for-profit sectors. Changes in
treatment guidelines should be accompanied by subse-
quent implementation activities, which should involve all
sector players. The assumption that providers will follow
the guidelines on paper is merely a guess and therefore
there is need for frequent sensitization through education,
information and communication. Furthermore, monito-
ring and evaluation for the achievements and failures of
the policy changes and subsequent re-planning for better
results is compulsory. This will increase rational use of
anti-malarials and reduce parasitic resistance to recom-
mended drugs.
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